1. Pink Sheet
  2. >>Geography
  3. >>Europe

Leo Pharma Aims To Extend Reach Of Dermatology Business With Global Expansion And Picato’s Green Light For Europe

 
• By John Davis

Danish dermatology specialist Leo Pharma is hunting for new pipeline assets after its next major product – Picato gel – got the green light from Europe’s top regulator.

With its leading research product, the actinic keratosis therapy Picato (ingenol mebutate) gel, recommended for approval in Europe Sept. 20 by the European Medicine Agency’s key Committee for Medicinal Products for Human Use, or CHMP, and after a 60% jump in headcount over the past four years, Denmark’s Leo Pharma AS is looking for new collaborations, partnerships and acquisitions to fuel the next stage of its global expansion program.

Leo acquired the rights to Picato from the Australian/U.S. company Peplin Ltd., which it bought for $287.5 million in 2009 Also see "Skin Tight: Dermatology Specialty Leo Pharma...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

EMA Touts Faster Global Post-Approval Changes Via Regulatory Reliance

 
• By Eliza Slawther

The European Medicines Agency says that a regulatory reliance pilot that it is supporting to speed up assessments of post-approval changes appears to be accelerating evaluation timelines in non-EU countries.

UK And US Regulators In Sync On RWD External Control Arms

 
• By Vibha Sharma

The UK regulator’s draft guideline on the use of external control arms based on real-world data reflects concepts similar to those outlined by the US Food and Drug Administration.

New EU Approvals

 
• By Neena Brizmohun

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include two new products, one of which is Vyjuvek, Krystal Biotech's advanced therapy for treating dystrophic epidermolysis bullosa.